Mulele Kalima1, Kennedy Lishimpi, Jane L Meza, Shinobu Watanabe-Galloway, Susan C Msadabwe, Catherine K Mwaba, Aaron L Shibemba, Lewis Banda, Charles Wood, Robert M Chamberlain, Amr S Soliman. 1. *Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE; †Cancer Diseases Hospital, Lusaka, Zambia; ‡Faculty of Medical Radiation Sciences, Lusaka Apex Medical University, Lusaka, Zambia; §Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha; ∥Nebraska Center for Virology, University of Nebraska-Lincoln, Lincoln, NE; and ¶Department of Epidemiology, MD Anderson Cancer Center, University of Texas, Houston, TX.
Abstract
OBJECTIVES: Cervical cancer is increasing but underestimated in developing countries. We calculated the observed and expected incidence of cervical cancer in Lusaka and Southern and Western provinces of Zambia. METHODS/MATERIALS: Data for 2007 to 2012 were obtained for the 3 provinces. Data included age, residence, year of diagnosis, marital status, occupation, human immunodeficiency virus (HIV), stage, radiotherapy, and chemotherapy. Expected incidence in Southern and Western provinces was calculated based on observed incidence for Lusaka province, adjusting for HIV. RESULTS: Crude and age-standardized incidence rates (ASRs) in Lusaka were 2 to 4 times higher than incidence in the other 2 provinces. Lusaka had a rate of 54.1 per 10(5) and ASR of 82.1 per 10(5) in the age group of 15 to 49 years. The Southern province had a rate of 17.1 per 10(5) and ASR of 25.5 per 10(5); the Western province had a rate of 12.3 per 10(5) and ASR rate of 17.2 per 10(5). The observed cervical cancer incidence rates in the Southern and Western provinces were lower than the rate in Lusaka, possibly because of the uncertainty of underreporting/underdiagnosis or actual lower risk for reasons yet unclear. The HIV seroprevalence rates in patients from the 3 provinces were 46% to 93% higher than seroprevalence in the respective general populations. CONCLUSIONS: Cervical cancer is significantly underestimated in Zambia, and HIV has a significant role in pathogenesis. Future studies should establish methods for case ascertainment and better utilization of hospital- and population-based registries in Zambia and other similar developing countries.
OBJECTIVES:Cervical cancer is increasing but underestimated in developing countries. We calculated the observed and expected incidence of cervical cancer in Lusaka and Southern and Western provinces of Zambia. METHODS/MATERIALS: Data for 2007 to 2012 were obtained for the 3 provinces. Data included age, residence, year of diagnosis, marital status, occupation, human immunodeficiency virus (HIV), stage, radiotherapy, and chemotherapy. Expected incidence in Southern and Western provinces was calculated based on observed incidence for Lusaka province, adjusting for HIV. RESULTS: Crude and age-standardized incidence rates (ASRs) in Lusaka were 2 to 4 times higher than incidence in the other 2 provinces. Lusaka had a rate of 54.1 per 10(5) and ASR of 82.1 per 10(5) in the age group of 15 to 49 years. The Southern province had a rate of 17.1 per 10(5) and ASR of 25.5 per 10(5); the Western province had a rate of 12.3 per 10(5) and ASR rate of 17.2 per 10(5). The observed cervical cancer incidence rates in the Southern and Western provinces were lower than the rate in Lusaka, possibly because of the uncertainty of underreporting/underdiagnosis or actual lower risk for reasons yet unclear. The HIV seroprevalence rates in patients from the 3 provinces were 46% to 93% higher than seroprevalence in the respective general populations. CONCLUSIONS:Cervical cancer is significantly underestimated in Zambia, and HIV has a significant role in pathogenesis. Future studies should establish methods for case ascertainment and better utilization of hospital- and population-based registries in Zambia and other similar developing countries.
Authors: Mulindi H Mwanahamuntu; Vikrant V Sahasrabuddhe; Sharon Kapambwe; Krista S Pfaendler; Carla Chibwesha; Gracilia Mkumba; Victor Mudenda; Michael L Hicks; Sten H Vermund; Jeffrey S A Stringer; Groesbeck P Parham Journal: PLoS Med Date: 2011-05-17 Impact factor: 11.069
Authors: V V Sahasrabuddhe; M H Mwanahamuntu; S H Vermund; W K Huh; M D Lyon; J S A Stringer; G P Parham Journal: Br J Cancer Date: 2007-04-17 Impact factor: 7.640
Authors: Mulindi H Mwanahamuntu; Vikrant V Sahasrabuddhe; Meridith Blevins; Sharon Kapambwe; Bryan E Shepherd; Carla Chibwesha; Krista S Pfaendler; Gracilia Mkumba; Belington Vwalika; Michael L Hicks; Sten H Vermund; Jeffrey Sa Stringer; Groesbeck P Parham Journal: PLoS One Date: 2013-09-18 Impact factor: 3.240
Authors: Christopher Ng'andwe; John J Lowe; Paula J Richards; Lara Hause; Charles Wood; Peter C Angeletti Journal: BMC Infect Dis Date: 2007-07-16 Impact factor: 3.090
Authors: Mario Jesus Trejo; Kennedy Lishimpi; Mulele Kalima; Catherine K Mwaba; Lewis Banda; Alick Chuba; Eslone Chama; Susan C Msadabwe; Melanie L Bell; Robin B Harris; Elizabeth Jacobs; Amr Soliman Journal: Int J Gynecol Cancer Date: 2020-03-21 Impact factor: 3.437
Authors: Mario Jesus Trejo; Amr S Soliman; Yuli Chen; Mulele Kalima; Alick Chuba; Eslone Chama; Catherine K Mwaba; Lewis Banda; Kennedy Lishimpi Journal: Int J Gynaecol Obstet Date: 2021-07-14 Impact factor: 4.447
Authors: Mariah P Gesink; Robert M Chamberlain; Julius Mwaiselage; Crispin Kahesa; Kahima Jackson; William Mueller; Jane L Meza; Amr S Soliman Journal: BMC Cancer Date: 2020-09-30 Impact factor: 4.430